/
DBVT
$16.00-$0.01 (-0.06%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$947.6M
59M shares
52-week range
$8.51 – $26.19
42% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
8.69%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-38.60
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.8M | $14.7M | $11.3M | $5.7M | $4.8M | $15.7M | $0 | $0 |
| Cost of revenue | $5.0M | $0 | $0 | $9.3M | $20.3M | $0 | $6.8M | $17.7M |
| Gross profit | $12.8M | $14.7M | $11.3M | −$3.6M | −$15.5M | $15.7M | −$6.8M | −$17.7M |
| Gross margin | 100.0% | 100.0% | 100.0% | -62.5% | -322.9% | 100.0% | — | — |
| R&D | $123.5M | $112.2M | $101.6M | $70.3M | $75.5M | $60.2M | $89.9M | $116.7M |
| Operating income | −$190.1M | −$171.0M | −$158.8M | −$98.6M | −$96.6M | −$76.4M | −$120.5M | −$147.1M |
| EBITDA | −$206.2M | −$168.4M | −$124.8M | −$91.2M | −$76.7M | −$63.3M | −$111.0M | −$139.3M |
| Net income | −$190.3M | −$172.0M | −$159.6M | −$97.8M | −$96.3M | −$72.7M | −$113.7M | −$146.9M |
| Net margin | -1484.7% | -1169.5% | -1415.0% | -1713.5% | -2006.3% | -462.4% | — | — |
| EPS (diluted) | -3.05 | -2.90 | -2.95 | -1.80 | -1.25 | -0.75 | -1.20 | -1.70 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3M | $-0.80 | $-1.09–$-0.60 | 3 |
| 2027 | $90M | $-0.41 | $-0.52–$-0.31 | 2 |
| 2028 | $292M | $0.03 | $0.02–$0.03 | 1 |
| 2029 | $663M | $0.46 | $0.34–$0.58 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.72
Price
$16.00
Implied downside
-89%
Peer comparison
DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
www.dbv-technologies.com- Employees
- 161
- IPO / List date
- Oct 22, 2014
- HQ
- CHATILLON, I0
Held by traders on TradeandTell
No one on the platform currently holds DBVT.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in DBVT as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-11-29 | 1-for-5reverse |
| 2024-06-07 | 1-for-2reverse |
Recent trades on TradeandTell
No one on the platform has traded DBVT yet.
